about
Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilmsDrug repurposing and human parasitic protozoan diseasesPharmacological advances in the treatment of invasive candidiasis.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.2-Amino-nonyl-6-methoxyl-tetralin muriate inhibits sterol C-14 reductase in the ergosterol biosynthetic pathway.A newly identified derivative of amphotericin B: isolation, structure determination and primary evaluation of the activity and toxicity.Overcoming antifungal resistance.Influence of the freeze-drying process on the physicochemical and biological properties of pre-heated amphotericin B micellar systemsDifferential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BAtrioventricular block related to liposomal amphotericin B.Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosisEfficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice.Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosisThe interaction of dipole modifiers with polyene-sterol complexesSalvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.From nature to the laboratory and into the clinicMulticenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of MucoralesSafety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Antifungal therapy and outcomes in infants with invasive Candida infections.Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study.Recent advances in antifungal pharmacotherapy for invasive fungal infections.Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.Distinct stages during colonization of the mouse gastrointestinal tract by Candida albicansCharacterization of a Polyethylene Glycol-Amphotericin B Conjugate Loaded with Free AMB for Improved Antifungal Efficacy.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsExperience with community-based amphotericin B infusion therapy.Liposomal amphotericin B: clinical experience and perspectives.Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.Emerging echinocandins for treatment of invasive fungal infections.Treatment options for invasive fungal infections.Amphotericin B-associated hyperbilirubinemia: case report and review of the literature.Fungal pneumonia due to molds in patients with hematological malignancies.Micafungin: a new echinocandin antifungal.Immunomodulatory therapy in yeast infections.An update on the use of antifungal agents.Coccidioidomycosis and pregnancy: a review.
P2860
Q26861656-62AC6916-828D-4E71-BCAB-7EDE194ED3ACQ26999453-649B1B17-9959-4F58-BC4F-749136A81E82Q33232599-8DE42D5A-A21B-4F42-9CB4-408233A311C4Q33409652-B7249DD1-4ACA-4A00-822C-00DC178CDE28Q33556437-9045F5E5-8B3A-49B8-9269-135466E50C37Q33626386-9D61E970-7E5D-48A7-BB66-C468DBC08E80Q33651853-0711C261-5DC0-4AF4-A4A3-EE4C0C50A02EQ33681274-F0928C03-88A5-4A81-ABA3-1DC993BC3533Q33722067-49C99A1B-F7F6-40C1-8E8D-52116990AAE7Q33744152-1170CD50-7A5C-48E8-9952-501FA9033E34Q33883785-6460B832-606D-48B2-AE99-F23ACAB52DC6Q33947926-C07662C0-7763-417E-8D4E-071ECDA691B6Q34352109-AEEB8650-0320-4BFA-BAAC-ACA0F0510E5BQ34428184-A26F80B0-DA86-4899-A10D-F702CBE93BFFQ34543970-84CF4BA6-455B-4F77-BCD3-5C027C0324A7Q34657694-BB42AB51-C518-4A87-BB1B-BF710B6C087CQ35076896-68C5215F-F995-4B86-9C1C-0F9E3C1D87B3Q35715408-F69496CA-0B81-4581-8778-938F57D0E532Q35746695-8C1827BC-5343-4C6D-BE56-7D23B282E5A9Q35897495-CC6EE9CC-88E0-4C68-A2D0-1C759938615AQ35899223-E6312A37-F3AC-4687-8DB1-3DA6370028D1Q35917383-67AB0E3D-8883-422E-AD48-74D615F52DCAQ35917392-7174D5F8-45A3-4C65-980F-816B1E552786Q35918461-1CB01AD7-B0A1-488C-A30B-7C05B993A118Q35967724-6C255F2E-736B-4F2A-9075-976A5328FE0FQ36018713-EF4D6867-87A6-4516-9E50-FCB8D513F1F9Q36087577-CADEB9D8-EE22-4CEF-969E-2CC96CCB2CE9Q36130619-244746C1-40FE-4975-A0D8-A2C3FDC4A3C6Q36140647-A84C2155-6E29-498A-82B1-0CD8BC9740F4Q36326220-EF7AD731-B827-45B1-8C1A-E2B5784BA399Q36364064-61D4A889-EA2F-401A-9F88-AADDAA38410FQ36383044-394FF73A-0854-4D0F-8EBD-097F1F53D001Q36458402-C816D5BB-E0D8-4CF3-806E-64A3390A3ED6Q36484945-03672836-254E-4085-AB9A-37D30C5E6008Q36551571-3A8DDE7E-FDF9-46BC-B3F3-A5D6F572C564Q36616182-18ABD11C-7353-4FAA-AFBF-722DA9971F6AQ36693843-BE718DB6-7922-4DD7-9509-415D19E65473Q36723814-646C48A7-81BC-439F-9AA5-4C63A4B01FDBQ36724783-FD0D9211-6414-4678-842D-2F84003A4042Q36760951-6DD434F8-C165-4DF4-9CE1-2493D20B27F9
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Amphotericin B: time for a new "gold standard".
@en
Amphotericin B: time for a new "gold standard".
@nl
type
label
Amphotericin B: time for a new "gold standard".
@en
Amphotericin B: time for a new "gold standard".
@nl
prefLabel
Amphotericin B: time for a new "gold standard".
@en
Amphotericin B: time for a new "gold standard".
@nl
P2093
P2860
P356
P1476
Amphotericin B: time for a new "gold standard"
@en
P2093
Kieren A Marr
Luis Ostrosky-Zeichner
Stuart H Cohen
P2860
P304
P356
10.1086/376634
P407
P50
P577
2003-07-22T00:00:00Z